Effectiveness of Gefitinib against Non–Small-Cell Lung Cancer with the Uncommon EGFR Mutations G719X and L861QSatoshi Watanabe, Kunihiko Kobayashi, Akira Inoue et al.|Journal of Thoracic Oncology|2014Cited by 204
NEJ026: Phase III study comparing bevacizumab plus erlotinib to erlotinib in patients with untreated NSCLC harboring activating EGFR mutationsMakoto Maemondo, T. Nukiwa, Tatsuro Fukuhara et al.|Annals of Oncology|2016Cited by 6